HASSELT, Belgium, July 27 /PRNewswire-FirstCall/ -- Biotechnology company MabCure, Inc. (OTC Bulletin Board: MBCI) today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood.
Diagnosis and Treatment of Epithelial Ovarian Cancer
Ovarian cancer represents about 25% of all female genital tract malignancies However, there are more deaths from ovarian cancer each year in the United States than from endometrial cancer and cervical cancer combined
Psychic Source Partners with National Ovarian Cancer Coalition during National Ovarian Cancer Awareness Month
Psychic Source is doing its part to help spread awareness about ovarian cancer. As part of National Ovarian Cancer Awareness month in September, Psychic Source will donate 2 percent of its sales to the National Ovarian Cancer Coalition (NOCC) during the week of September 13-19. The funds will support NOCC's mission to raise awareness and promote education about ovarian cancer.
